ClinicalTrials.gg
CompletedNCT04643678Updated Aug 16, 2022

Anakinra in the Management of COVID-19 Infection

A Phase 2/3 interventional study of Anakinra and Standard of Care in Covid19, Pneumonia and Cytokine Release Syndrome, sponsored by Hamad Medical Corporation. Completed at 1 site in Qatar. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-16.

Sponsored by Hamad Medical Corporation · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Interleukin 1 Receptor Antagonist Protein in COVID-19 — 3 open to participants now, 3 under way, 3 of them phase 3. Interleukin 1 Receptor Antagonist Protein · COVID-19.

Enrollment
10th of 15
80 · median 150
Started
2020
with 11 others
Phase 2/3
2 of 15
1 open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Hamad Medical Corporation

Among the 15 studies testing Interleukin 1 Receptor Antagonist Protein in COVID-19, this one is the 10th largest by enrollment, is one of 12 that started in 2020, is one of 2 in phase 2/3, and was the 12th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 15 studies testing Interleukin 1 Receptor Antagonist Protein in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Interleukin 1 Receptor Antagonist Protein

Interleukin 1 Receptor Antagonist Protein: first FDA approval 2001 (KINERET), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Interleukin 1 Receptor Antagonist Protein in COVID-19, or all of them as a file.
02

Study summary

Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes.

Anakinra - an interleukin (IL)-1 receptor antagonist - had showed survival benefits in patients with macrophage activation syndrome (MAS) and sepsis and was investigated for the use in COVID-19 infection with promising outcomes.

03

Conditions studied

  • Covid19
  • Pneumonia
  • Cytokine Release Syndrome
  • Corona Virus Infection
  • Viral Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized adult (age ≥ 18yrs)
  • Confirmed COVID-19 diagnosis
  • Presence of respiratory distress in addition to signs of cytokine release syndrome
  • Radiological evidence of pneumonia
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Known allergic reactions to the study medication or any component of the product.
  • Active bacterial, viral, TB, fungal infectious diseases
  • Received or immunomodulatory in the past 30 days
  • \< 500 cells/microliter
  • \< 50,000/microliter
  • Pregnant or breastfeeding females
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Anakinra Group

    Anakinra + Standard of Care

    Drug: Anakinra

  • Other
    Standard of Care Group

    Standard of Care Alone

    Other: Standard of Care

Interventions

  • Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care

    Also known as: Kineret®

  • OtherStandard of Care

    Patients will receive the Standard of Care therapy as per the local treatment protocol

06

What researchers measure

Primary outcomes

  1. Treatment Success at day 14

    Defined as WHO Clinical Progression score of ≤3 \[Ambulatory mild disease: symptomatic; assistance needed\].

    Time frame: Day 14

Secondary outcomes

  1. Change in WHO Clinical Progression Score

    Change in WHO Clinical Progression Score between day 1 and day 7 \[WHO Clinical Progression score: 0 (Uninfected) - 10 (Dead)\]

    Time frame: Day 7

  2. Time to ICU admission

    Time to ICU admission up to 28 days

    Time frame: Day 28

  3. Incidence of Adverse Events

    Incidence of adverse events up to 28 days

    Time frame: Day 28

  4. Length of hospital stay

    Length of hospital stay up to 28 days

    Time frame: Day 28

  5. All-cause Mortality

    All-cause mortality rate at hospital discharge or at 28 days, whichever is first

    Time frame: Day 28

07

Study locations

1 site
  • Hamad Medical Corporation
    Doha, Qatar
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Mar 2021, 4 months.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2020
First posted
Nov 25, 2020
StartActual
Oct 30, 2020
Primary completionActual
Mar 1, 2021
CompletionActual
Apr 30, 2021
Last update
Aug 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04643678
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Oct 30, 2020
Primary completion
Mar 1, 2021
Completion
Apr 30, 2021
Last update
Aug 16, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein

Start the discussion